The Multidrug-Resistant Organism Repository and Surveillance Network (MRSN) Acinetobacter baumanii diversity panel consists of 100 multidrug-resistant A. baumanii strains selected from a collection of over 3,500 clinical isolates collected between 2001 and 2017 from health care facilities around the world.1 This panel supports the research and development of new antibiotics and tools to treat infections caused by A. baumannii, an opportunistic pathogen and leading cause of infections in hospital and healthcare settings, and categorized by the World Health Organization as a priority 1 pathogen due to its increasing rates of antibiotic resistance.
The panel represents 70 different traditional Pasteur scheme multilocus sequence types, including genetically distinct isolates within the most globally prevalent clones, and contains multidrug-resistant, extensively drug-resistant and non-multidrug-resistant isolates with 100 distinct alleles encompassing 32 families of antimicrobial resistance genes. Isolates are fully characterized using whole genome sequencing complete with antibiotic susceptibility and antimicrobial-resistant gene content, ranging from pansensitive to panresistant phenotypes, and a comprehensive susceptibility profile consisting of 14 clinically relevant antibiotics.
The MRSN Acinetobacter baumanii Diversity Panel (BEI Resources NR-52148 through NR-52248) is currently in production and individual strains will be available on the BEI Resources website as they are released. The complete panel of 100 isolates will be available as BEI Resources NR-52248 later this year.
- Galac, M. R., et al. “A Diverse Panel of Clinical Acinetobacter baumannii for Research and Development.” Antimicrob. Agents Chemother. 64 (2020): e00840-20. PubMed: 32718956.
Image: Photograph of Acinetobacter baumannii cultured on sheep blood agar medium (CDC/Todd Parker)